Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease
- 29 January 2021
- journal article
- research article
- Published by Wiley in Archiv der Pharmazie
- Vol. 354 (5) , e2000467
Abstract
A series of urolithin amide (i.e., URO‐4–URO‐10 and THU‐4–THU‐10) derivatives was designed and synthesized, and their chemical structures were confirmed with spectroscopic techniques and elemental analysis. The title compounds and synthesis intermediates (THU‐1–THU‐10 and URO‐1–URO‐10) were evaluated for their potential to inhibit acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and monoamine oxidase B (MAO‐B). Compounds THU‐4 and THU‐8 were found to be the most potent inhibitors for the cholinesterases and MAO‐B, respectively. The docking studies were also employed to evaluate the binding modes of the most active compounds with AChE, BuChE, and MAO‐B. Furthermore, the moderate‐to‐strong activities of the compounds were also displayed in amyloid‐beta inhibition and antioxidant assay systems. The results pointed out that the urolithin scaffold can be employed in drug design studies for the development of multitarget ligands acting on various cascades shown to be important within the pathophysiology of Alzheimer's disease.Keywords
This publication has 35 references indexed in Scilit:
- The chemistry toolbox of multitarget-directed ligands for Alzheimer's diseaseEuropean Journal of Medicinal Chemistry, 2019
- 2019 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2019
- Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesteraseBioorganic Chemistry, 2018
- Multifunctional cholinesterase inhibitors for Alzheimer's disease: Synthesis, biological evaluations, and docking studies of o/p‐propoxyphenylsubstituted‐1H‐benzimidazole derivativesArchiv der Pharmazie, 2018
- Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammationRedox Biology, 2016
- Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised TrialsPLOS Medicine, 2007
- Memantine in Moderate-to-Severe Alzheimer's DiseaseNew England Journal of Medicine, 2003
- Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's diseaseThe Lancet, 1994
- Muscarinic and nicotinic contributions to cognitive function and cortical blood flowNeurobiology of Aging, 1992
- NON-CHOLINERGIC NEUROTRANSMITTER ABNORMALITIES IN ALZHEIMER'S DISEASEBritish Medical Bulletin, 1986